VR Logo

TransCode Therapeutics Inc. (RNAZ) download report

Healthcare | Biotechnology & Pharma Research

TransCode Therapeutics Inc. (RNAZ) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

Get the Stocks!

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease.

IPO Date: 08-Jul-2021

Co-Founder, CEO, Pres & Director: Mr. Robert Michael Dudley

CFO, VP of Admin. & Director: Mr. Thomas A. Fitzgerald M.B.A.

Listing: NASDAQ: RNAZ

Country: United States

Headquarters: Boston, MA

Website: https://www.transcodetherapeutics.com

Key Facts

Market cap: $16.71 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-5.83 Mln

Cash: $16.85 Mln

Total Debt: $0.00 Mln

Insider's Holding: 32.62%

Liquidity: Low

52 Week range: $1.15 - 7.00

Shares outstanding: 12,977,200

Stock Performance

Time Period TransCode Therapeutics (RNAZ) S&P BSE Sensex* S&P Small-Cap 600*
YTD-50.39-8.99-19.22
1 month-31.15-3.40-9.34
3 months-53.85-8.50-14.58
1 Year--0.89-17.64
3 Years--10.415.91
5 Years--11.435.64
10 Years--11.7710.10
As on 29-Jun-2022 *As on 30-Jun-2022
AMCs: